Epstein Secrets

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.1 <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular risk according

LYMPHOCYTES 2298 ABSOLUTE MONOCYTES 492 ABSOLUTE EOSINOPHILS 270 ABSOLUTE BASOPHILS 48 NEUTROPHILS 48.2 LYMPHOCYTES 38.3 MONOCYTES 8.2 EOSINOPHILS 4.5 BASOPHILS 0.8 URINALYSIS, COMPLETE Sim Endhoto I IRON AND TOTAL IRON BINDING CAPACITY Reference Range 4.8-5.6 mg/dL 4.0-8.0 mg/dL 0.40

dL 11.0-15.0 % 140-400 Thousand/uL 7.5-12.5 fL 1500-7800 cells/uL 850-3900 cells/uL 200-950 cells/uL 15-500 cells/uL 0-200 cells/uL Lab MI HS CRP PERFORMING SITE: MI QUEST DIAGNOSTICS.MIAMI. HMO COMMERCE PARKWAY. MIRAMAR. FL 33015.3938 Laboratocc Outdo': JULIE I. FRIEDMAN.MD.CLIA. IOD0277334

LYMPHOCYTES 2509 ABSOLUTE MONOCYTES 507 ABSOLUTE EOSINOPHILS 390 ABSOLUTE BASOPHILS 72 NEUTROPHILS 46.5 LYMPHOCYTES 38.6 MONOCYTES 7.8 EOSINOPHILS 6.0 BASOPHILS 1.1 PENDING TESTS: Reference Range 40-115 U/L 10-35 U/L 9-46 U/L 3.8-10.8 Thousand/uL 4.20-5.80 Million/uL 13.2-17.1 g/dL 3

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/dL (talc) <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular r

LYMPHOCYTES 2880 ABSOLUTE MONOCYTES 705 ABSOLUTE EOSINOPHILS 435 ABSOLUTE BASOPHILS 60 NEUTROPHILS 45.6 LYMPHOCYTES 38.4 MONOCYTES 9.4 EOSINOPHILS 5.8 BASOPHILS 0.8 URINALYSIS, COMPLETE See Endnote 2 VITAMIN B12 423 C-REACTIVE PROTEIN 1.5 TESTOSTERONE, TOTAL MALES (ADULT), IA TESTOST

ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

LYMPHOCYTES 2221 ABSOLUTE MONOCYTES 454 ABSOLUTE EOSINOPHILS 390 ABSOLUTE BASOPHILS 38 NEUTROPHILS 51.5 LYMPHOCYTES 34.7 MONOCYTES 7.1 EOSINOPHILS 6.1 BASOPHILS 0.6 URINALYSIS, COMPLETE COLOR YELLOW APPEARANCE CLEAR SPECIFIC GRAVITY 1.023 PH < OR 5.0 GLUCOSE NEGATIVE BILIRUBIN N

ith diabetes plus I major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/c1L) is considered a therapeutic option. HS CRP 1.3 Average relative cardiovascular risk according to MIA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

0 cells/uL ABSOLUTE EOSINOPHILS 443 15-500 colls/uL ABSOLUTE BASOPHILS 59 0-200 cells/uL NEUTROPHILS 48.8 LYMPHOCYTES 34.2 MONOCYTES 8.5 EOSINOPHILS 7.5 BASOPHILS 1.0 URINALYSIS, COMPLETE MI See Sndnote VITAMIN 612 371 200-1100 pg/m1 M1 Please Note: Although the reference range for vita

ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

LYMPHOCYTES 2221 ABSOLUTE MONOCYTES 454 ABSOLUTE EOSINOPHILS 390 ABSOLUTE BASOPHILS 38 NEUTROPHILS 51.5 LYMPHOCYTES 34.7 MONOCYTES 7.1 EOSINOPHILS 6.1 BASOPHILS 0.6 URINALYSIS, COMPLETE COLOR YELLOW APPEARANCE CLEAR SPECIFIC GRAVITY 1.023 PH < OR 5.0 GLUCOSE NEGATIVE BILIRUBIN N